Darshana Zaveri, Partner
Darshana joined Catalyst in 2006 and became Partner in 2011. She is an active member of the investment team and focuses on all aspects of investing including deal sourcing, diligence and management. She led Catalyst's investments in Hepregen, Augmenix, and Lantos Technologies. She currently serves on the board of Lantos and observes on the boards of Hepregen, Augmenix, and Allegro Diagnostics. Prior to Catalyst, she was an investigator at Vertex Pharmaceuticals, Inc. where she focused on drug development programs in oncology, metabolic disease, and immunology. Previously she worked at Genome Therapeutics Corporation, a Massachusetts-based biotechnology company, at the Dana Farber Cancer Institute and interned at the United Nations and Innovest Strategic Advisory Services. Darshana has authored several publications, including scientific journal articles. She received an MPA from Harvard University, a Master in Cell and Molecular Biology from Boston University, and a BS in Biochemistry from Bombay University in Bombay, India.